Compare MTCH & CYTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MTCH | CYTK |
|---|---|---|
| Founded | 1986 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.6B | 8.0B |
| IPO Year | 2015 | 2004 |
| Metric | MTCH | CYTK |
|---|---|---|
| Price | $31.20 | $62.60 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 11 | 16 |
| Target Price | $35.55 | ★ $82.38 |
| AVG Volume (30 Days) | ★ 3.4M | 2.3M |
| Earning Date | 02-03-2026 | 02-26-2026 |
| Dividend Yield | ★ 2.40% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.15 | N/A |
| Revenue | ★ $3,469,367,000.00 | $87,211,000.00 |
| Revenue This Year | $2.06 | $339.72 |
| Revenue Next Year | $3.38 | $79.08 |
| P/E Ratio | $14.72 | ★ N/A |
| Revenue Growth | N/A | ★ 2609.26 |
| 52 Week Low | $26.39 | $29.31 |
| 52 Week High | $39.20 | $70.98 |
| Indicator | MTCH | CYTK |
|---|---|---|
| Relative Strength Index (RSI) | 36.27 | 47.75 |
| Support Level | $31.35 | $60.30 |
| Resistance Level | $32.15 | $65.08 |
| Average True Range (ATR) | 0.67 | 2.91 |
| MACD | -0.10 | -0.01 |
| Stochastic Oscillator | 2.45 | 45.74 |
Match Group Inc is a provider of online dating products. The company's portfolio of brands includes Tinder, Hinge, Match, Meetic, OkCupid, Pairs, Plenty Of Fish, Azar, BLK, and more, each built to increase its user's likelihood of connecting with others. The company has four operating segments: Tinder, Hinge, Evergreen and Emerging, and Match Group Asia. The company generates the majority of its revenue from the Tinder segment.
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.